346 related articles for article (PubMed ID: 35883484)
21. An Insight of Scientific Developments in TSC for Better Therapeutic Strategy.
Natarajan N; Thiruvenkatam V
Curr Top Med Chem; 2020; 20(23):2080-2093. PubMed ID: 32842942
[TBL] [Abstract][Full Text] [Related]
22. Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb.
Tee AR; Manning BD; Roux PP; Cantley LC; Blenis J
Curr Biol; 2003 Aug; 13(15):1259-68. PubMed ID: 12906785
[TBL] [Abstract][Full Text] [Related]
23. Loss of expression of tuberin and hamartin in tuberous sclerosis complex-associated but not in sporadic angiofibromas.
Fackler I; DeClue JE; Rust H; Vu PA; Kutzner H; Rütten A; Kaddu S; Sander CA; Volkenandt M; Johnson MW; Vinters HV; Wienecke R
J Cutan Pathol; 2003 Mar; 30(3):174-7. PubMed ID: 12641776
[TBL] [Abstract][Full Text] [Related]
24. Post-translational Regulation of FNIP1 Creates a Rheostat for the Molecular Chaperone Hsp90.
Sager RA; Woodford MR; Backe SJ; Makedon AM; Baker-Williams AJ; DiGregorio BT; Loiselle DR; Haystead TA; Zachara NE; Prodromou C; Bourboulia D; Schmidt LS; Linehan WM; Bratslavsky G; Mollapour M
Cell Rep; 2019 Jan; 26(5):1344-1356.e5. PubMed ID: 30699359
[TBL] [Abstract][Full Text] [Related]
25. Tuberous sclerosis: immunohistochemistry expression of tuberin and hamartin in a 31-week gestational fetus.
Vinaitheerthan M; Wei J; Mizuguchi M; Greco A; Barness EG
Fetal Pediatr Pathol; 2004; 23(4):241-9. PubMed ID: 16095035
[TBL] [Abstract][Full Text] [Related]
26. Identification of regions critical for the integrity of the TSC1-TSC2-TBC1D7 complex.
Santiago Lima AJ; Hoogeveen-Westerveld M; Nakashima A; Maat-Kievit A; van den Ouweland A; Halley D; Kikkawa U; Nellist M
PLoS One; 2014; 9(4):e93940. PubMed ID: 24714658
[TBL] [Abstract][Full Text] [Related]
27. Nutrient-induced FNIP degradation by SCFβ-TRCP regulates FLCN complex localization and promotes renal cancer progression.
Nagashima K; Fukushima H; Shimizu K; Yamada A; Hidaka M; Hasumi H; Ikebe T; Fukumoto S; Okabe K; Inuzuka H
Oncotarget; 2017 Feb; 8(6):9947-9960. PubMed ID: 28039480
[TBL] [Abstract][Full Text] [Related]
28. Signaling events downstream of mammalian target of rapamycin complex 2 are attenuated in cells and tumors deficient for the tuberous sclerosis complex tumor suppressors.
Huang J; Wu S; Wu CL; Manning BD
Cancer Res; 2009 Aug; 69(15):6107-14. PubMed ID: 19602587
[TBL] [Abstract][Full Text] [Related]
29. Tuberous sclerosis as an underlying basis for infantile spasm.
Yeung RS
Int Rev Neurobiol; 2002; 49():315-32. PubMed ID: 12040899
[TBL] [Abstract][Full Text] [Related]
30. Mourning Dr. Alfred G. Knudson: the two-hit hypothesis, tumor suppressor genes, and the tuberous sclerosis complex.
Hino O; Kobayashi T
Cancer Sci; 2017 Jan; 108(1):5-11. PubMed ID: 27862655
[TBL] [Abstract][Full Text] [Related]
31. TSC1 and TSC2: genes that are mutated in the human genetic disorder tuberous sclerosis.
Sampson JR
Biochem Soc Trans; 2003 Jun; 31(Pt 3):592-6. PubMed ID: 12773162
[TBL] [Abstract][Full Text] [Related]
32. The expression of hamartin, the product of the TSC1 gene, in normal human tissues and in TSC1- and TSC2-linked angiomyolipomas.
Plank TL; Logginidou H; Klein-Szanto A; Henske EP
Mod Pathol; 1999 May; 12(5):539-45. PubMed ID: 10349994
[TBL] [Abstract][Full Text] [Related]
33. The tuberin-hamartin complex negatively regulates beta-catenin signaling activity.
Mak BC; Takemaru K; Kenerson HL; Moon RT; Yeung RS
J Biol Chem; 2003 Feb; 278(8):5947-51. PubMed ID: 12511557
[TBL] [Abstract][Full Text] [Related]
34. The tuberous sclerosis complex genes in tumor development.
Mak BC; Yeung RS
Cancer Invest; 2004; 22(4):588-603. PubMed ID: 15565817
[TBL] [Abstract][Full Text] [Related]
35. The association of neurodevelopmental abnormalities, congenital heart and renal defects in a tuberous sclerosis complex patient cohort.
Robinson J; Uzun O; Loh NR; Harris IR; Woolley TE; Harwood AJ; Gardner JF; Syed YA
BMC Med; 2022 Apr; 20(1):123. PubMed ID: 35440050
[TBL] [Abstract][Full Text] [Related]
36. Simultaneous loss of hamartin and tuberin from the cerebrum, kidney and heart with tuberous sclerosis.
Mizuguchi M; Ikeda K; Takashima S
Acta Neuropathol; 2000 May; 99(5):503-10. PubMed ID: 10805093
[TBL] [Abstract][Full Text] [Related]
37. Tumour suppressors hamartin and tuberin: intracellular signalling.
Krymskaya VP
Cell Signal; 2003 Aug; 15(8):729-39. PubMed ID: 12781866
[TBL] [Abstract][Full Text] [Related]
38. The Hsp90 chaperone machinery: conformational dynamics and regulation by co-chaperones.
Li J; Soroka J; Buchner J
Biochim Biophys Acta; 2012 Mar; 1823(3):624-35. PubMed ID: 21951723
[TBL] [Abstract][Full Text] [Related]
39. Tuberous sclerosis complex: genetics to pathogenesis.
Narayanan V
Pediatr Neurol; 2003 Nov; 29(5):404-9. PubMed ID: 14684235
[TBL] [Abstract][Full Text] [Related]
40. Aha-type co-chaperones: the alpha or the omega of the Hsp90 ATPase cycle?
LaPointe P; Mercier R; Wolmarans A
Biol Chem; 2020 Mar; 401(4):423-434. PubMed ID: 31782942
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
